Corvus Pharmaceuticals (CRVS) Enterprise Value (2022 - 2025)
Corvus Pharmaceuticals (CRVS) has 4 years of Enterprise Value data on record, last reported at -$2.9 million in Q3 2025.
- For Q3 2025, Enterprise Value rose 38.74% year-over-year to -$2.9 million; the TTM value through Sep 2025 reached -$2.9 million, up 38.74%, while the annual FY2024 figure was -$8.7 million, 30.74% up from the prior year.
- Enterprise Value reached -$2.9 million in Q3 2025 per CRVS's latest filing, up from -$14.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$2.9 million in Q3 2025 and bottomed at -$31.5 million in Q1 2022.
- Average Enterprise Value over 4 years is -$13.7 million, with a median of -$12.6 million recorded in 2023.
- The widest YoY moves for Enterprise Value: up 76.72% in 2024, down 93.8% in 2024.
- A 4-year view of Enterprise Value shows it stood at -$13.2 million in 2022, then rose by 4.1% to -$12.6 million in 2023, then soared by 30.74% to -$8.7 million in 2024, then soared by 67.2% to -$2.9 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$2.9 million in Q3 2025, -$14.7 million in Q2 2025, and -$5.0 million in Q1 2025.